🟢 Natera is trading 12.30% up in pre-market after Q2 earnings beat and raised 2026 guidance

Natera is trading at $298.01 (+12.30%) after a Q2 earnings beat that included $752.8 million in revenue, up 37.7% year over year.

• Management raised 2026 revenue guidance to $2.85 billion-$2.91 billion, a $100 million midpoint increase.
• Oncology testing volumes jumped 57.2%, and total quarterly tests exceeded 1.04 million.
• The earnings beat and stronger outlook clearly explain the August 7, 2026 pre-market surge.